207 related articles for article (PubMed ID: 35880455)
1. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
Baeuerle PA; Wesche H
Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
[TBL] [Abstract][Full Text] [Related]
2. Development of T-cell engagers selective for cells co-expressing two antigens.
Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
[TBL] [Abstract][Full Text] [Related]
3. Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors.
Berman DM; Bell JI
Clin Cancer Res; 2023 Feb; 29(4):697-704. PubMed ID: 36255733
[TBL] [Abstract][Full Text] [Related]
4. T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy.
Li Y; Zhao W; Shen Y; Xu Y; Chen S; Pan L
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672132
[TBL] [Abstract][Full Text] [Related]
5. [Bispecific antibodies targeting CD3 in oncology and hematology].
Vanacker H; Vinceneux A; Nicolas-Virelizier E; Brahmi M; Cassier PA
Bull Cancer; 2021 Oct; 108(10S):S181-S194. PubMed ID: 34920802
[TBL] [Abstract][Full Text] [Related]
6. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
7. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
[TBL] [Abstract][Full Text] [Related]
9. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Friedrich MJ; Neri P; Kehl N; Michel J; Steiger S; Kilian M; Leblay N; Maity R; Sankowski R; Lee H; Barakat E; Ahn S; Weinhold N; Rippe K; Bunse L; Platten M; Goldschmidt H; Müller-Tidow C; Raab MS; Bahlis NJ
Cancer Cell; 2023 Apr; 41(4):711-725.e6. PubMed ID: 36898378
[TBL] [Abstract][Full Text] [Related]
10. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
Chervin AS; Stone JD; Konieczna I; Calabrese KM; Wang N; Haribhai D; Dong F; White MK; Rodriguez LE; Bukofzer GT; Ellis PA; Cosgrove C; Hecquet C; Clarin JD; Palma JP; Reilly EB
Mol Cancer Ther; 2023 Aug; 22(8):903-912. PubMed ID: 37294945
[TBL] [Abstract][Full Text] [Related]
11. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
[TBL] [Abstract][Full Text] [Related]
12. Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors.
Voynov V; Adam PJ; Nixon AE; Scheer JM
Antibodies (Basel); 2020 Nov; 9(4):. PubMed ID: 33217946
[TBL] [Abstract][Full Text] [Related]
13. Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model.
Zorn JA; Wheeler ML; Barnes RM; Kaberna J; Morishige W; Harris M; Huang RY; Lohre J; Chang YC; Chau B; Powers K; Schindler I; Neradugomma N; Thomas W; Liao X; Zhou Y; West SM; Wang F; Kotapati S; Chen G; Yamazoe S; Kosenko A; Dollinger G; Sproul T; Rajpal A; Strop P
Sci Rep; 2022 Mar; 12(1):3530. PubMed ID: 35241687
[TBL] [Abstract][Full Text] [Related]
14. An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Ishiguro T; Sano Y; Komatsu SI; Kamata-Sakurai M; Kaneko A; Kinoshita Y; Shiraiwa H; Azuma Y; Tsunenari T; Kayukawa Y; Sonobe Y; Ono N; Sakata K; Fujii T; Miyazaki Y; Noguchi M; Endo M; Harada A; Frings W; Fujii E; Nanba E; Narita A; Sakamoto A; Wakabayashi T; Konishi H; Segawa H; Igawa T; Tsushima T; Mutoh H; Nishito Y; Takahashi M; Stewart L; ElGabry E; Kawabe Y; Ishigai M; Chiba S; Aoki M; Hattori K; Nezu J
Sci Transl Med; 2017 Oct; 9(410):. PubMed ID: 28978751
[TBL] [Abstract][Full Text] [Related]
15. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
[TBL] [Abstract][Full Text] [Related]
16. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
17. T-cell-engaging Therapy for Solid Tumors.
de Miguel M; Umana P; Gomes de Morais AL; Moreno V; Calvo E
Clin Cancer Res; 2021 Mar; 27(6):1595-1603. PubMed ID: 33082210
[TBL] [Abstract][Full Text] [Related]
18. Overcoming the challenges associated with CD3+ T-cell redirection in cancer.
Singh A; Dees S; Grewal IS
Br J Cancer; 2021 Mar; 124(6):1037-1048. PubMed ID: 33469153
[TBL] [Abstract][Full Text] [Related]
19. A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity.
Boustany LM; LaPorte SL; Wong L; White C; Vinod V; Shen J; Yu W; Koditek D; Winter MB; Moore SJ; Mei L; Diep L; Huang Y; Liu S; Vasiljeva O; West J; Richardson J; Irving B; Belvin M; Kavanaugh WM
Cancer Res; 2022 Nov; 82(22):4288-4298. PubMed ID: 36112781
[TBL] [Abstract][Full Text] [Related]
20. T-cell-engaging bispecific antibodies in cancer.
van de Donk NWCJ; Zweegman S
Lancet; 2023 Jul; 402(10396):142-158. PubMed ID: 37271153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
